Clinical Summary Resource

Share

Program Content

Activities

  • ADCs for B-Cell Lymphoma
    Antibody–Drug Conjugates for B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • Bispecific Abs in B-Cell Lymphomas
    Bispecific Antibodies in B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • BTKi for B-Cell Lymphomas
    BTK Inhibitors for B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • CAR T-cells for B-Cell Lymphomas
    CAR T-cell Therapy in B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • IMiDs and ICIs for B-Cell Lymphomas
    Immunomodulatory Agents and Immune Checkpoint Inhibitors in B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • Ab-Based Tx in B-cell Lymphomas
    Antibody-Based Therapies for B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity
  • XPO1 Inhibitors for B-Cell Lymphomas
    XPO1 and Nuclear Export Inhibitors in B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2022

    Expires: March 21, 2023

    View Activity

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Genentech, a member of the Roche Group

Genmab US Inc and AbbVie

Karyopharm Therapeutics

Novartis Pharmaceuticals Corporation